Effect of PEG-irinotecan in cancer

Trial Profile

Effect of PEG-irinotecan in cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors 3SBio
  • Most Recent Events

    • 09 Mar 2016 New trial record
    • 07 Mar 2016 According to 3SBio media release, company received IND approval from the CFDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top